# Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

> **NCT05012254** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación GECP** · enrollment: 71 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Brain Metastases, Adult
- Lung Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT05012254
- **Lead sponsor:** Fundación GECP
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-18
- **Primary completion:** 2027-10-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05012254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05012254, "Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05012254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*